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Purpose: To report the occurrence and management of severe infectious scleritis in a 75 year-old woman
following intravitreal ranibizumab injection.
Observations: A 75 year-old monocular woman receiving monthly intravitreal ranibizumab injection for
wet age related macular degeneration in the left eye presented with severe dull pain, decreased vision,
and scleral melt with discharge 2 weeks after her last injection. The dilated fundus exam was devoid of
vitritis. The patient was admitted to our hospital for both diagnostic and therapeutic purposes. She was
initially started on aggressive oral and topical antibiotics, but showed no signiﬁcant improvement. The
scleral cultures were positive for Pseudomonas aeruginosa. In view of the aggressive nature of her
infection, intravenous antibiotics were added to the treatment regimen. The patient recovered her
baseline visual function after two weeks of intravenous, oral and, topical antibiotics.
Conclusion and importance: To our knowledge, this is the ﬁrst case of anterior infectious necrotizing
scleritis secondary to Pseudomonas aeruginosa infection following intravitreal ranibizumab injection.
Clinicians performing intravitreal injections should have a high index of suspicion for iatrogenic in-
fections including scleritis and endophthalmitis, as these infections require aggressive topical and sys-
temic antibiotics as well as possible hospitalization.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1 The injection protocol included a drop of topical anesthesia followed by a drop
of 5% povidone-iodine applied at the following times: 30 minutes before the in-1. Introduction
Necrotizing anterior scleritis is the most severe form of infec-
tious scleritis and represents a serious threat to vision.1,2 This
presents with a gradual onset of pain that becomes extreme,
persistent and may radiate to the temple, brow or jaw.1,2 Scleral
involvement is characterized by severe vasculitis and closure of the
episcleral vascular bed with apparent areas of capillary non-
perfusion, infarction, and necrosis of the involved area.1 The
extent of scleral necrosis may either be sectoral or diffuse and may
also rapidly progress, exposing the underlying choroid.1 Dissemi-
nating inﬂammation with involvement of the cornea, ciliary body,
and trabecular meshwork is common and may result in severe
ocular morbidity including, keratitis, anterior uveitis, and elevated
intraocular pressure.1oussa).
Inc. This is an open access article u1.1. Case report
A 75 year-old woman, known for controlled hypertension and
dyslipidemia, was followed for geographic atrophy secondary to
age related macular degeneration (AMD) in the right eye (OD) and
exudative AMD in the left eye (OS), for which she was being treated
with ranibizumab intravitreal injections (inferotemporal quadrant
of injection). Her baseline best corrected visual acuity (BCVA) was
CF at 1 m OD and 20/50 OS. Her right eye showed signiﬁcant
macular scarring and an advanced cataract.
Two weeks following her 20th intravitreal injection in the left
eye by the same retina specialist,1 the patient presented withjection, 5 minutes before the injection and 30 seconds before the injection. A lid
speculum was used and the injection of anti-VEGF was made in the inferotemporal
quadrant. Both patient and doctor employed no talking during the injection pro-
cedure. The retina specialist performing the injection did not wear gloves during
the procedure. However, both hands were thoroughly cleaned with waterless soap
alcohol-based solution using 20 seconds of scrub. Furthermore, no hand jewelry
was worn during the procedure.
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CF and IOP was 12 mmHg, respectively. The slit lamp exam showed
4þ conjunctival injection, 3þ inferotemporal corneal folds and
1þ anterior chamber cells, in addition to an inferotemporal 12 mm
(horizontally) by 6 mm (vertically) area of white scleral necrosis
with an overlying epithelial defect (Fig. 1A and B). This area was
adjacent to an anterior 5 mm by 3 mm area of scleral thinning
characterized by uveal show (Fig. 1A and B). The dilated fundus
exam was within her baseline without any vitritis or vitreal in-
ﬁltrates. There were also no pertinent ﬁndings on B-scan ultraso-
nography. The working diagnosis was infectious scleritis. The
patient was then started on ciproﬂoxacin 500mg po BID and topical
fortiﬁed vancomycin 50 mg/ml and tobramycin 14 mg/ml q1h,
alternating every 30 minutes. The sclera was cultured for bacteria
and fungus.
The patient denied any autoimmune diseases, recent trauma,
and travel history. However, an immunological and infectious blood
workup as well as a chest x-ray were ordered to rule out serious
conditions including sarcoidosis and tuberculosis. The patient was
then admitted for further management due to the severity of her
condition. Infectious disease services were consulted for co-
management of the patient condition.
The workup was negative for autoimmune diseases and the
scleral cultures were positive for Pseudomonas aeruginosa. Despite
the initial treatment, the patient showed new satellite lesions and
enlargement of the necrotic area with increased scleral thinning
and signiﬁcantly dilated scleral vessels on further follow-ups
(Fig. 1CeE). A second scleral culture was also positive for Pseudo-
monas aeruginosa.
In view of the lack of signiﬁcant improvement, a more aggres-
sive treatment was started under the guidance of the infectious
disease services. The modiﬁed treatment consisted of two weeks of
topical fortiﬁed tobramycin q1h, topical ciproﬂoxacin QID, intra-
venous meropenem 2g q8h and intravenous tobramycin 7 mg/kg
(430mg) once daily. She remained on this treatment regimen for 2
weeks during which signiﬁcant improvement in her ocular status
was noted (Fig. 1FeH). The patient was discharged after 3 weeks of
in-patient stay with a BCVA of 20/50 after pinhole correction, IOP of
12 mmHg, ½þ anterior chamber cells and 1þ corneal folds.
Importantly, the necrotic scleral area was reduced to 7 mm by 2.5
mm (Fig. 1I and J). The antibiotic regimen was tapered to topical
fortiﬁed tobramycin q6h for 3 days while keeping ciproﬂoxacin,
both topically QID and 500 mg po BID for a total of 10 weeks post
discharge. The patient was then followed closely and remained
stable.
At six-month follow-up, her BCVA and IOP were 20/50 and
13 mmHg, respectively. The previously infected scleral area was
completely healed (4.5 mm by 2 mm) but nonetheless markedly
thinned (Fig. 1KeM). The choroidal neovascular lesion has
remained inactive after one year follow-up and repeated OCT ex-
aminations. The patient did not need further injections. Her vision
remains stable at 20/50 at one year follow-up.
2. Discussion
Inﬂammatory disorders of the sclera comprise diverse clinical
presentations and encompass a broad spectrum of etiologies
ranging from idiopathic to autoimmune to infectious.1,2 Though
infectious etiologies of scleritis are rare, representing about 5e10%
of cases, the high disease burden associated with infectious scleritis
warrants its increased scrutiny.2
The main etiology of infectious scleritis is predominantly bacte-
rial.2 Pseudomonas aeruginosa is the most common organism
implicated in this condition, isolated from up to 85% of bacterial
cultures.2,3 This has been associated with post-traumatic or post-surgical processes in several recent studies.4,5 Cases following pte-
rygium surgery are most frequently reported, but infectious scleritis
has also been described after excisions of conjunctival neoplasms, as
well as cataract, vitreoretinal, and glaucoma surgeries.3,4,6e8
The most feared complication of intravitreal injections is
endophthalmitis. Its incidence varies between studies and ranges
between 0.0053% (equivalent to 1 in every 18,839 injections)9 and
0.21%.10 Staphylococcus and Streptococcus species are reported to
be the most and second most common infectious organisms. In a
study by Simunovic et al., coagulase negative Staphylococcus,
Streptococcus and Staphylococcus aureus represented 42.4%, 39.4%
and 9.1%, respectively, of the microbiologic proﬁle of post-
intravitreal injections related endophthalmitis.11
Currently, there is still no preferred method for reducing the
incidence of post-intravitreal injections endophthalmitis. The use
of topical antibiotics after intravitreal injection is still controversial.
In fact, one study found no statistical differences in the incidence of
post-intravitreal injections endophthalmitis (0.052% in the group
with antibiotics vs. 0.048% in the group without antibiotics12).
Compared to povidoneeiodine alone before intravitreal injections,
the combination of topical antibiotics and povidoneeiodine did not
statistically reduce the incidence of post-intravitreal injections
endophthalmitis.13 Furthermore, the repeated use of topical anti-
biotics can predispose to antibiotic resistance.14
The use of 5% povidoneeiodine on the lids and ocular surface is
a very common standard practice. Applying povidoneeiodine 30
seconds before the injections was shown to statistically reduce the
conjunctival bacterial load.15 Interestingly, the bactericidal effect of
a single drop of povidoneeiodine was estimated to be equivalent to
a three-day course of topical antibiotics.16
The high rate of contamination with Staphylococcus and
Streptococcus species was thought to be related to inoculation from
oropharyngeal ﬂora.17 The use of a surgical mask was associated
with a signiﬁcant statistical reduction in bacterial colonies
compared to no-mask technique.18 Along the same reasoning, Garg
et al. showed a statistically signiﬁcant reduction in the rate of post-
injection endophthalmitis following strict 'No-Talking' policy dur-
ing injection procedure19.
Speculum placement prior to injections was not reported to
affect the conjunctival bacterial counts.15 The use of gloves and/or
patient draping is not a standard ofﬁce practice. It is likely more
common in Europe where intravitreal injections are administered
in operating rooms. The latter practice was associated with a lower
rate of endophthalmitis compared to in-ofﬁce injections as per
Abell et al.20.
Infectious necrotizing scleritis, although extremely rare, is
another very severe ocular complication that is occasionally iatro-
genic. To our knowledge, this is the ﬁrst case of anterior infectious
necrotizing scleritis secondary to Pseudomonas aeruginosa infection
following intravitreal ranibizumab injection. Our initial treatment
was likely not sufﬁcient given the aggressiveness of the bacteria
and the severity of the infection. However, our revised treatment
protocol eliminated the infection effectively and restored the pa-
tient's visual function.
Clinicians performing intravitreal injections should have a high
index of suspicion for iatrogenic infections including scleritis and
endophthalmitis, especially in patients with poor baseline visual
acuity. Referral to anterior segment specialists should be without
delay as such severe infections are not only difﬁcult to diagnose and
manage, but also require aggressive topical and systemic antibiotics
and possible hospitalization.
Patient consent
The patient consented in writing to publication of the case.
Fig. 1. OS Anterior infectious necrotizing scleritis. AeB. Photos taken at presentation showing an inferotemporal 12 mm horizontal by 6 mm vertical area of white scleral necrosis
with an overlying epithelial defect. This area was adjacent to an anterior 5 mm horizontal by 3 mm vertical area of scleral thinning characterized by uveal show. CeE. Photos taken
four days after presentation showing signiﬁcant worsening of the infectious process that is characterized by new nasal and temporal satellite lesions, enlargement of the necrotic
area with increased scleral thinning and signiﬁcantly dilated scleral vessels. FeH. Photos taken 1 week after presentation while on intravenous meropenem and intravenous
tobramycin. There is signiﬁcant improvement in the size of the necrotic area. IeJ. Photos at discharge following 2 weeks of intravenous treatment. There is marked shrinkage of the
necrotic scleral area to 7 mm horizontal by 2.5 mm vertical. KeM. Photos taken six months post discharge showing a ﬁnal necrotic healed area of 4.5 mm horizontal by 2 mm
vertical with a resultant uveal show.
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